Replies to post #292678 on NorthWest Biotherapeutics Inc (NWBO)

[anders2211]

well good question.

To uplist to the Nasdaq a company must have a minimum SP of $ 4, a minimum of 1,250,000 publicly traded shares.

For NWBO to get to a MC of 4 billion I do think they will have to make some sort of a deal with a large investor and or have a serious amount in royalty payment from a big pharma.

An R/S is really a desperate attempt in most cases to keep the company afloat. It would have made more sense for NWBO to have done so a year ago. So no I dont think that NWBO will reverse split after positive topline data. I think NWBO will partner MC will get to over 4 billion and then list up (as part of the terms with the investor). Most companies have done it in this manner. However, this is NWBO, one never knows for sure..

[Poor Man -]

Well, the basic reason why reverse splits don’t work is that those company’s are typically not performing well to begin with, so of course the stock will keep going down.

In a situation like NWBO, assuming good results, a r/s would likely help, if not in the immediate short run, certainly upon uplisting. The issue with this company for the uplist is not just the stock price. It’s the corporate governance and management thatNasdaq staff will have heartburn.

[OilPatch]

Some companies will reverse split under the "guise" of a NASDAQ listing play in order to further dilute.

Its rare but some companies will reverse split in order to upgrade to a higher exchange. Investor sentiment usually causes it to tank, especially since its traded on the OTC, if its well run it can do it.

An RS is not the case here IMO.

[HappyLibrarian]

Any R/S needs to come after TLD has shown us the color of their money and forced the moment of reckoning to occur with the FDA. Even then it is bad for retail.

Doing an R/S prior to clear and incontrovertible game changing news signals another ripoff.